bladder cancer

News

AZ plots wider Imfinzi use in bladder cancer after trial win

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in early bladder cancer.

News

Data readout puts J&J's bladder cancer drug back on track

New data in non-muscle-invasive bladder cancer (NMIBC) has backed up Johnson & Johnson's faith in its TAR-200 drug candidate.

News

At-home tablet now an option for NHS bladder cancer patients

The first targeted drug for a common form of bladder cancer that can be taken at home. J&J's Balversa, has been backed for NHS use.

News

Yellow water balloon and hand with needle

J&J files intravesical bladder cancer drug TAR-200 in US

Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).

News

Setback for J&J's TAR-200 bladder cancer programme

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme.

News

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.

AZ plots wider Imfinzi use in bladder cancer after trial win

Data readout puts J&J's bladder cancer drug back on track

At-home tablet now an option for NHS bladder cancer patients

J&J files intravesical bladder cancer drug TAR-200 in US

Setback for J&J's TAR-200 bladder cancer programme

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

bladder cancer

Editor's Picks